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Urokinase-induced mitogenesis is mediated by casein kinase 2
and nucleolin
I. Dumler*, V. Stepanova*†, U. Jerke*, O.A. Mayboroda‡, F. Vogel*, P. Bouvet§,
V. Tkachuk†, H. Haller# and D.C. Gulba*
Background: Urokinase (uPA) and the urokinase receptor (uPAR) form a
multifunctional system capable of concurrently regulating pericellular
proteolysis, cell-surface adhesion, and mitogenesis. The role of uPA and
uPAR in directed proteolysis is well established and its function in cellular
adhesiveness has recently been clarified by numerous studies. The
molecular mechanisms underlying the mitogenic effects of uPA and uPAR
are still unclear, however.
Results: We identified mechanisms that might participate in uPA-related
mitogenesis in human vascular smooth muscle cells and demonstrated that
uPA induces activation of a unique signaling complex. This complex contains
uPAR and two additional proteins, nucleolin and casein kinase 2, which are
implicated in cell proliferation. Both proteins were isolated by affinity
chromatography on uPA-conjugated cyanogen-bromide-activated Sepharose
4B and were identified using nano-electrospray mass spectrometry and
immunoblotting. We used laser scanning and immunoelectron microscopy
studies to further demonstrate that nucleolin and casein kinase 2 are located
on the cell surface where they colocalize with the uPAR. Moreover, the
proteins were co-internalized into the cell as an entire complex.
Immunoprecipitation experiments in combination with an in vitro kinase assay
demonstrated a specific association of uPAR with nucleolin and casein
kinase 2 and revealed a uPA-induced activation of casein kinase 2, which
presumably led to phosphorylation of nucleolin. Blockade of nucleolin and
casein kinase 2 with specific modulators led to the inhibition of uPA-induced
cell proliferation.
Conclusions: We conclude that in human vascular smooth muscle cells, uPA
induces the formation and activation of a newly identified signaling complex
comprising uPAR, nucleolin, and casein kinase 2, that is responsible for the
uPA-related mitogenic response. The complex is not a unique feature of vascular
smooth muscle cells, as it was also found in other uPAR-expressing cell types.
Background
Abnormal accumulation of proliferating neointimal vascu-
lar smooth muscle cells (VSMCs) is a prominent feature of
several vascular diseases, including atherosclerosis and
restenosis [1]. Excessive VSMC proliferation can be initi-
ated by several growth factors, including platelet-derived
growth factor, fibroblast growth factor, and epidermal
growth factor, all of which are released in response to arte-
rial injury [2–4]. A growing body of evidence, however,
implies that the fibrinolytic system, in particular uro-
kinase-type plasminogen activator, might contribute sig-
nificantly to vascular remodeling, most likely by affecting
cellular migration and proliferation.
Urokinase (uPA) and its specific receptor (uPAR) form a
multifunctional system capable of concurrently regulating
pericellular proteolysis, cell-surface adhesion, and mitoge-
nesis (for reviews see [5,6]). The role of uPA and uPAR in
directed proteolysis is well established and its function in
cellular adhesiveness has been clarified by numerous
studies (see [5,6] and references therein). The mitogenic
effects of the complex remain the least well understood
aspect of uPA and uPAR action, however. The data avail-
able to date confirm the mitogenic response to uPA in a
wide variety of cell types. Nevertheless, the data are con-
tradictory in terms of the underlying molecular mecha-
nisms. It is unclear whether or not induction of cell
proliferation requires the complete uPA molecule or only
its amino-terminal fragment (ATF), which is catalytically
inactive but still binds to the uPAR [7–9]. Furthermore,
the absolute necessity of uPAR for uPA-related cell prolif-
eration is also unclear [10–13]. Finally, additional, as yet
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unidentified, membrane-associated proteins might be
involved in uPA-induced signal transduction that culmi-
nates in cell proliferation [14].
The possibility that the mitogenic responses related to
uPA and uPAR are highly cell-specific cannot be excluded,
which implies some structural specificity and underscores
the diversity of underlying signaling events. Although the
uPA–uPAR system is known to possess a high signaling
capacity by inducing the activation of numerous pathways
[15–25], the requirement of this signaling for cell prolifera-
tion is still unclear. These considerations prompted us to
study the molecular mechanisms whereby uPA affects cell
proliferation. Here we report that in human coronary artery
VSMCs, uPA induces cell proliferation through the activa-
tion of a signaling complex that contains, in addition to
uPAR, two additional proteins, which were identified as
nucleolin and casein kinase 2 (CK2).
Results
The uPAR complex contains nucleolin
We used affinity purification on uPA-conjugated
cyanogen-bromide (CNBr)-activated Sepharose 4B to eval-
uate the association of uPAR with additional proteins. On
the assumption that the interaction of uPAR with its
natural ligand might lead to the activation of the receptor
and associated proteins, and because protein phosphoryla-
tion is one of the most frequent activation events, we com-
bined this assay with in vitro kinase reactions. Several
prominent protein bands were seen after Coomassie stain-
ing, with one 100 kDa band being heavily phosphorylated
(Figure 1a,b). This band was cut out from the gel and sub-
jected to in-gel tryptic cleavage followed by nano-electro-
spray mass spectrometry. Four sequenced peptides were
found to be identical to sequences within human nucleolin
[26]. Peptide 1, TGISDVFAK (using the single-letter
amino-acid code), was identical to residues 324–332;
peptide 2, EVFEDAAEIR, to residues 410–419; peptide 3,
GLSEDTTEETLK, to residues 577–588; and peptide 4,
GFGFVDFNSEEDAK, to residues 610–623. In western
blot analysis, an anti-nucleolin monoclonal antibody specif-
ically recognized this protein (Figure 1c), whereas the anti-
uPAR antibody confirmed the affinity elution of uPAR
from the Sepharose 4B matrix (Figure 1d). To exclude the
possibility that the co-isolation of uPAR and nucleolin was
due to the non-specific co-purification of nucleolin as a
contaminant, immunoprecipitation experiments were per-
formed. Anti-uPAR antibody was able to specifically co-
precipitate nucleolin (Figure 1e) and vice versa: the uPAR
was co-immunoprecipitated when anti-nucleolin antibody
was used (Figure 1f).
Nucleolin is co-localized with uPAR on the cell surface and
the two are co-internalized 
Nucleolin is an abundant nuclear phosphoprotein that
shuttles between the nucleus and cytoplasm and that, in
some instances, is also located on the cell surface
(reviewed in [27]). To examine the presence of nucleolin
on the plasma membrane of VSMCs, we first used
immunofluorescent laser scanning microscopy. Immuno-
labeling of non-permeabilized cells using anti-nucleolin
monoclonal antibody revealed nucleolin at the cell surface
(Figure 2a) where uPAR was recognized by anti-uPAR
polyclonal antibodies (Figure 2b). Interestingly, double-
staining of the proteins showed a pronounced co-localiza-
tion pattern when the images were superimposed
(Figure 2c). To exclude the possibility that the surface
staining of nucleolin on non-permeabilized cells might be
due to the exposition of the cell interior, methanol-perme-
abilized samples were used for the control staining
(Figure 2d,e). In permeabilized cells, intensive nuclear
staining of nucleolin was observed, whereas intracellular
staining of uPAR, which is a membrane-attached protein,
was, as expected, very weak. The staining patterns of per-
meabilized and non-permeabilized cells were completely
different in that a punctate staining pattern typical of cell-
surface proteins was seen only in non-permeabilized cells.
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Figure 1
Nucleolin and uPAR co-eluted after affinity matrix precipitation and
co-immunoprecipitated with anti-uPAR and anti-nucleolin antibodies.
(a) Coomassie staining and (b) phosphorylation profile of VSMC
eluates from control and uPA-conjugated CNBr-activated Sepharose
4B. The arrowheads indicate the phosphorylated protein band that
was subjected to in-gel tryptic cleavage and microsequencing.
(c,d) Aliquots of eluted proteins were separated by SDS–PAGE and
then western blotted with (c) anti-nucleolin or (d) anti-uPAR antibody.
(e) Anti-uPAR or (f) anti-nucleolin antibody was used to
co-immunoprecipitate uPAR and nucleolin from VSMCs. The
immunoprecipitates were then analyzed with (e) anti-nucleolin or
(f) anti-uPAR antibody. The arrowheads indicate the proteins of
interest. Note that the 100 kDa nucleolin band in (a,b) is indicated
below the 97 kDa marker; this might result from the slower motility of
protein markers in the large gels used in these experiments aimed at
protein identification by sequence analysis.
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To further characterize the membrane distribution of
uPAR and nucleolin, immunoelectron microscopy was
performed using the primary antibodies described above
and gold-particle-coupled secondary antibodies. Pre-
embedding double-labeling experiments were first per-
formed to confirm the colocalization of the proteins
observed with immunofluorescent staining The antibod-
ies revealed that both the receptor and nucleolin were
located on the cell surface. The two types of gold parti-
cles were simultaneously present on the plasma mem-
brane, with high densities observed over areas rich in
invaginations (Figure 3a,b). To follow the process of
protein internalization, incubation with both gold-labeled
secondary antibodies was performed at room temperature
after a constant labeling period with the primary antibod-
ies at 4°C to prevent internalization. The incubation with
the secondary antibodies under these conditions permit-
ted the internalization process. The uPAR and nucleolin
were internalized in large part simultaneously and were
found together  in vesicles of different shapes and sizes
after only 10 minutes of internalization (Figure 3c–e).
Casein kinase 2 is associated with the uPAR–nucleolin
complex and is activated by uPA
Nucleolin is a natural substrate for CK2, the enzyme that
plays a decisive role in mitogenic signal transduction [28].
To address our hypothesis that CK2 might function as an
ecto-enzyme in the uPAR–nucleolin complex, several
approaches were used. First, we used uPA-conjugated
Sepharose for the affinity elution of CK2 under the condi-
tions described above for the uPAR and nucleolin co-
purification. The eluates were subjected to SDS–PAGE
and immunoblotting with anti-CK2 monoclonal antibody.
As shown in Figure 4a, CK2 was specifically eluted from
this matrix; no band corresponding to CK2 was observed
after elution from the control matrix. The association of
CK2 with the uPAR–nucleolin complex was further
demonstrated in  co-immunoprecipitation experiments.
Anti-uPAR and anti-nucleolin antibodies specifically co-
precipitated CK2 (Figure 4b,c), whereas the anti-CK2
antibody was able to effectively co-precipitate both uPAR
and nucleolin (Figure 4d,e).
To analyze the possible co-localization of CK2, uPAR and
nucleolin on the cell surface, an immunocytochemical study
was performed. Immunostaining of non-permeabilized
VSMCs with the anti-CK2 monoclonal antibody revealed
that CK2 localized at the cell surface (Figure 5a,e). Double
staining of non-permeabilized cells with different combi-
nations of anti-CK2 (Figure 5a,e), anti-uPAR (Figure 5b),
and anti-nucleolin (Figure 5d) antibodies clearly demon-
strated pronounced colocalization of these three proteins
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Figure 2
Co-localization of uPAR and nucleolin on the
cell surface. Non-permeabilized VSMCs were
fixed and stained for (a) nucleolin, using the
monoclonal anti-nucleolin antibody and Alexa
488-coupled secondary antibody and for
(b) uPAR, using the polyclonal anti-uPAR
antibody and Cy3-coupled secondary
antibody. (c) The superimposed composite
figure of nucleolin and uPAR from (a,b).
Yellow color denotes the colocalization of the
two proteins. (d,e) Control intracellular
staining of VSMCs permeabilzed with 80%
methanol at –20°C and stained as described
above for (d) nucleolin and (e) uPAR.
(a) (b) (c)
(e)
(d)
100 µm
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Figure 3
Co-localization and co-internalization of uPAR and nucleolin visualized by
immunoelectron microscopy. (a,b) Double immunolabeling with
polyclonal anti-uPAR (5 nm gold particles) and monoclonal anti-nucleolin
(12 nm gold particles) antibodies performed at 4°C. Labeling is seen on
the plasma membrane including the microvilli (arrowheads). (c–e) The
incubation with both gold-labeled secondary antibodies was performed
under conditions that permitted internalization for 10 min (see Materials
and methods for details). The labeling is seen on the plasma membrane,
with high densities over areas rich in invaginations (arrowheads), and in
cytoplasmic vacuoles (arrows). Magnification, × 112,000.
(a) (b)
(e)(d)
(c)
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(Figure 5c,f). As in the experiments described above,
methanol-permeabilized cells were used as a control for
intracellular staining of all three proteins (Figure 5g–i).
Further experiments investigated whether there is a func-
tional interrelationship between the components of the
revealed complex. To test for CK2 activity and its probable
regulation by uPA, an in vitro kinase assay was performed
with the immunoprecipitates obtained with the anti-CK2
antibody. Cells that were activated with uPA at different
time points were used. The results of these experiments
demonstrated that the CK2 activity of VSMCs increased
quickly and transiently in response to uPA, the activation
being observed within 5–10 minutes of uPA stimulation
(Figure 6a). The increase in CK2 activity, although reli-
able, was minor (about a two-fold increase). This small
increase might be explained by the fact that the anti-CK2
antibody precipitated the total pool of CK2 present in cell
lysates, whereas only cell-surface uPAR-associated enzyme
was supposedly uPA-sensitive. To prove this supposition,
further immunoprecipitation experiments were performed
using anti-uPAR and anti-nucleolin antibodies. The results
shown in Figure 6b clearly demonstrate that the uPAR
immunoprecipitates were indeed specifically enriched in
the uPA-activated CK2, whereas immunoprecipitation
with anti-nucleolin antibody did not allow distinction
between intracellular uPA-insensitive and surface-associ-
ated uPA-inducible CK2 (Figure 6b). 
CK2 and nucleolin are involved in the uPA-induced cell
proliferation
To assess the effects of CK2 activation on uPA-dependent
cell proliferation, VSMC proliferation was studied using a
DNA-synthesis assay. When added to growth-arrested
VSMCs, uPA exhibited a dose-dependent mitogenic effect
within 18 h; the half-maximal effect was observed at 50 nM
uPA (Figure 7a). As a positive control, the DNA synthesis
induced by 1% fetal calf serum (FCS) was obtained in every
assay (shown in the insets). To investigate whether or not
CK2 and nucleolin might contribute to the uPA-related
mitogenic pathway, VSMCs were first pretreated with mod-
ulators of CK2 activity, such as heparin and a CK2-substrate
peptide. Pretreatment of the cells with these agents pre-
vented uPA-induced stimulation of DNA synthesis,
whereas in the positive controls, pretreatment had no effect
on the mitogenic response to FCS (Figure 7b,c). In the next
set of experiments, VSMCs were pretreated with the RGG
peptide. The RGG motif was initially described as an
RNA-binding motif in several proteins [29–31]. The RGG
domain of nucleolin was recently demonstrated to be
involved in protein–protein interaction [32]. In our experi-
ments, the RGG peptide, at a concentration ranging from
0.3 to 3 µM, completely and specifically abolished the uPA-
induced increase in DNA synthesis (Figure 7d). Taken
together, these data demonstrate that CK2 and nucleolin
are involved in mitogenic response of VSMCs to uPA.
The complexes formed by uPAR, nucleolin and CK2 are not
found exclusively in VSMCs 
To elucidate whether or not the revealed association of
uPAR, nucleolin, and CK2 was specific only for VSMCs
or was of a more general nature, several cell types
expressing uPAR to different extents were studied
(Figure 8a). As a negative control, an LM-TK– cell line
lacking uPAR was used. The affinity co-elution of nucle-
olin and CK2 with uPAR was demonstrated for all cell
types used in these experiments, except the LM-TK–
cells (Figure 8b). Although nucleolin and CK2 were
present in the cell lysates (data not shown), no specific
binding of nucleolin and CK2 to the uPA-matrix was
observed when LM-TK– cells were used for affinity
purification. This confirms that uPAR was critical for
complex formation.
To investigate whether formation of the uPAR–CK2–nucle-
olin complex also has the same functional mitogenic conse-
quences in other uPAR-expressing cell types, proliferation
assays were performed as described above using uPA stimu-
lation and cell pretreatments with the CK2 substrate
peptide and the RGG peptide. The data obtained in these
experiments demonstrate that specific blockage of CK2 and
nucleolin led to the inhibition of uPA-induced mitogenic
response, not only in VSMCs, but in all uPAR-expressing
cell types tested (Figure 8c and data not shown). 
Discussion
The important findings in this study are that uPA induces
cell proliferation through the activation of a signaling
Research Paper  Urokinase-induced mitogenesis Dumler et al. 1471
Figure 4
Association of uPAR, CK2, and nucleolin in one complex. (a) Eluates
from control and uPA-conjugated CNBr-activated Sepharose 4B were
separated by SDS–PAGE and then western blotted with an antibody
raised against the alpha subunit of CK2 (CK2α). Immunoprecipitation
was performed from the VSMC lysates using (b) anti-uPAR,
(c) anti-nucleolin, or (d,e) anti-CK2 antibody. The immunoprecipitates
were then subjected to SDS–PAGE and analyzed by western blotting
with antibodies against (b,c) CK2, (d) uPAR, or (e) nucleolin.
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complex that contains, in addition to uPAR, two more
proteins, which we identified as nucleolin and CK2. Our
data are the first to demonstrate that CK2 and nucleolin
are specifically involved in the cell mitogenic response to
uPA. Thus, we suggest that the interaction of uPAR with
its ligand uPA leads to the activation of the ecto-protein
kinase CK2. The natural substrate of CK2, nucleolin,
might be phosphorylated and regulated in this way.
The uPAR is a glycosylphosphatidylinositol (GPI)-anchored
receptor and is devoid of a transmembrane or cytoplas-
mic domain [5,6]. Details on the transmembrane mito-
genic signaling of this receptor are still unclear. Evidence
implicates uPA and uPAR in the regulation of VSMC
growth [7–14]; however, the specific molecular mecha-
nisms underlying this regulation are still poorly understood.
Numerous studies, aimed at elucidating uPA-induced intra-
cellular signaling pathways leading to proliferation, have
revealed a high degree of diversity in different cell types.
The only known pathway of transmembrane uPAR signal-
ing is the physical interaction of uPAR with integrins,
which appears to have functional consequences [6].
Whether or not the variety of intracellular signaling path-
ways shown to be activated through uPAR are actually
mediated by integrins remains to be proved, however.
Most likely, some additional signal-eliciting interacting
partners for uPAR exist. In this respect, it is of special
importance to identify the still unknown cell-surface
proteins associated with uPA and uPAR, that enable the
transmission of mitogenic signals into the cell.
CK2 is a ubiquitous serine/threonine protein kinase impli-
cated in cell growth, proliferation, and remodeling (for
reviews see [33–35]). Interestingly, in addition to its local-
ization within the cytoplasm and the nucleus, CK2 is
located on the cell surface and acts as an ecto-enzyme,
contributing to ectophosphorylation of specific membrane
1472 Current Biology Vol 9 No 24
Figure 5
Figure 6
Activation of CK2 induced by uPA. VSMCs were stimulated with uPA,
immunoprecipitated with a control antibody and (a) an antibody
against CK2, (b) uPAR, or nucleolin and then measurements of CK2
activity were conducted and analyzed as described in the Materials
and methods. White bars show non-treated cells, grey bars show
uPA-stimulated cells.
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Colocalization of uPAR, casein kinase 2 and nucleolin on the cell
surface. Non-permeabilized VSMCs were fixed and stained for CK2
using the (a) monoclonal or (e) polyclonal anti-CK2 antibody and
Alexa 488 or Alexa 546-coupled secondary antibody. Cells were
stained for (b) uPAR using the polyclonal anti-uPAR antibody and
Cy3-coupled secondary antibody, or for (d) nucleolin using the
monoclonal anti-nucleolin antibody and Alexa 488-coupled
secondary antibody. (c,f) A double exposure of (c) CK2 and uPAR or
(f) CK2 and nucleolin staining, with colocalization appearing in
yellow. For the intracellular localization, VSMCs permeabilized with
80% methanol were stained as indicated above for (g) nucleolin,
(h) CK2, and (i) uPAR.
protein substrates. In this fashion, CK2 modulates the
functional properties of these substrates [36]. These
observations imply an important physiological regulatory
role for extracellular phosphorylation; however, the exact
mechanisms remain unclarified.
One CK2-specific substrate is nucleolin. CK2 phosphory-
lates nucleolin in vitro and has been co-purified with nucle-
olin as a tight complex [28,37]. Nucleolin is one of the most
abundant nuclear phosphoproteins implicated in pre-ribo-
somal RNA transcription and ribosome biogenesis [27].
One remarkable characteristic of nucleolin is that it shuttles
constantly between the nucleus and the cytoplasm [38] and
thereby might act as a carrier for ribosomal proteins [32].
Moreover, recent reports provide evidence that nucleolin
might also be localized on the cell surface, where it might
function as a cell-surface receptor or binding protein. Cell-
surface nucleolin has been reported to bind growth factors,
laminin, lipoproteins, a complement inhibitor Factor J, and
several viruses [39–45]. These findings raise the possibility
that the interaction between nucleolin and other mem-
brane-located proteins might represent a signaling mecha-
nism that modifies the cellular mitogenic response.
Our study demonstrates that uPAR, CK2 and nucleolin are
specifically associated in VSMCs and are co-localized on the
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Figure 7
Participation of CK2 and nucleolin in mediating
the mitogenic effect of uPA on VSMC.
(a) Quiescent cells were treated with
increasing concentrations of uPA in serum-free
medium. DNA synthesis was measured after
18 h using 5-bromo-2‚-deoxy-uridine (BrdU)
labeling. Cells were pretreated with the
indicated concentrations of (b) heparin,
(c) CK2-substrate peptide, or (d) RGG
peptide, or used without pretreatment (control).
DNA synthesis was determined in the uPA-
stimulated (grey bars) or non-stimulated (white
bars) cells. The recombinant RGG peptide was
prepared as described previously [8]. As a
positive control and a control for the inhibition
specificity, DNA synthesis induction with 1%
FCS was performed in each assay (shown in
the insets).
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Cell specificity of uPAR, CK2 and nucleolin association. (a) Expression
levels of uPAR in the indicated cell types was determined using the
uPAR–ELISA Kit (Monozyme). (b) Co-elution of nucleolin, CK2 and
uPAR from different cell types was performed using control and
uPA-conjugated CNBr-activated Sepharose 4B and analyzed by
immunoblotting as described in Figure 1 (see also the Materials and
methods). (c) Cell proliferation induced by uPA and cell pretreatments
with peptides were performed on human fibroblasts, as described for
VSMC in Figure 7. CASMC, coronary artery smooth muscle cells;
HT1080, human fibrosarcoma cell line HT1080; HF, human skin
fibroblasts; ECV, human umbilical vein endothelial cell line ECV-304;
LM–TK–, uPAR-deficient LM–TK— cell line.
cell surface, where they presumably form a functional
complex. CK2 and nucleolin were co-purified with uPAR
on the uPA-coupled affinity matrix and were specifically co-
precipitated with the anti-uPAR antibody. The cell-surface
localization of CK2 and nucleolin and their co-localization
with uPAR were shown by several sets of immuno-
microscopy experiments. We also showed that CK2 was
activated in response to uPA; this fact confirms the sup-
posed functional interrelations between the components of
the complex. Moreover, an in vitro kinase assay revealed a
high phosphorylation level of nucleolin affinity isolated on
the uPA-matrix, which might be due to nucleolin activation
within the complex initiated by uPA–uPAR binding.
Our results also suggest a functional role for the newly
identified complex, implicating the involvement of CK2
and nucleolin in the uPA-induced proliferation of VSMCs.
The mitogenic response to uPA observed in our experi-
ments is consistent with other reports demonstrating mito-
genic activity of uPA in different cell types [7–10,12,13]. It
is striking that the compounds known to specifically
inhibit CK2 and nucleolin completely abolished the uPA-
related mitogenic effect, whereas they had no influence
on the serum-induced cell proliferation. Thus, the most
potent of polyanionic CK2 inhibitors, heparin, used at
concentrations consistent with its IC50 value, eliminated
the increase in DNA synthesis induced by uPA. To
understand whether or not the contribution of CK2 to the
proliferative effect required the enzyme–substrate interac-
tion, a CK2-substrate peptide was used as a binding com-
petitor. These experiments documented the inhibition of
the VSMC mitogenic response to uPA upon the addition
of CK2 substrate in vitro in a dose-dependent manner.
The results suggest that an enzyme–substrate interaction
was involved. We used the recombinant RGG peptide to
further show that the uPA-induced pathway leading to cell
proliferation was modified when the nucleolin-binding
domain responsible for protein–protein interaction was
affected. These data suggest that the RGG domain of
nucleolin is implicated in complex formation, whereas the
amino-terminal domain, which possesses the sites of mul-
tiple phosphorylation [46], might be responsible for the
activation of nucleolin by CK2.
Interestingly, the complex was not unique to VSMCs, as
it was found in other uPAR-expressing cell types, such as
human fibroblasts, endothelial cells, and a tumor cell line.
The presence of uPAR appears to be the governing factor
for complex formation; thus, no uPA-related association
of nucleolin and CK2 was observed in the LM–TK– cell
line lacking uPAR. Although numerous studies suggest
that both CK2 and nucleolin might be directly involved
in the regulation of cell proliferation and mitotic dynam-
ics, the mechanisms of this signaling are still unclear. Our
electron microscopy studies demonstrated that nucleolin
co-localizes with uPAR to the cell surface and is rapidly
internalized. These findings might indicate a pathway for
intracellular translocation of the activated nucleolin.
Conclusions
Several different lines of evidence have converged to link
uPA and uPAR with an early signal for cell proliferation.
Our findings raise the possibility that the uPA-induced
mitogenic response might be realized through the forma-
tion and activation of a signaling complex comprising
uPAR, nucleolin and CK2. This signaling complex appears
to be of general biological importance because it was found
in all uPAR-expressing cell types tested. The recognition
of this pathway, coupled with our observation that heparin
influences this signaling, provides clinically relevant clues
to mechanisms and potential future interventions.
Materials and methods
Antibodies
Anti-uPAR polyclonal rabbit antibody (#399R) and monoclonal antibody
(#3937) were purchased from American Diagnostica, Inc. Monoclonal
anti-uPAR antibodies (#R-3-005) were from Monozyme, and a kind gift
of N. Brünner (Finsen Laboratories, Copenhagen, Denmark), polyclonal
goat anti-human uPAR antibody (#AF807) was from R+D system
GmbH. Antibodies against nucleolin were from Medical & Biological
Lab. Co. Monoclonal antibody to CK2α was obtained from Roche and
Calbiochem-Novabiochem GmbH, the polyclonal was from Calbiochem-
Novabiochem GmbH. Anti-CK2 rabbit antiserum was kindly provided by
O-G. Issinger (Biochemical Institute, Odense, Denmark). Alexa-488-
and Alexa-546-conjugated anti-mouse and anti-rabbit IgG were pro-
vided by Molecular Probes Inc., Cy3-conjugated anti-rabbit IgG was
from Jackson Immuno Research Laboratories. Secondary antibodies
coupled to 5 or 12 nm colloidal gold grains were purchased from
Dianova, horseradish-peroxidase-conjugated anti-mouse antibody was
from Santa Cruz Biotechnology, Inc., Sigma Chemicals Co. or Pierce.
Anti-rabbit horseradish-peroxidase-conjugated IgG was also from
Pierce. Antibodies for control experiments were purchased from Sigma
and Jackson Immuno Research Laboratories. Peroxidase-conjugated
AffiniPure mouse anti goat IgG (H+L) was from Dianova.
Cell culture
Human coronary artery VSMC were obtained from Clonetics. The cells
were grown in SmGM2 medium (Clonetics) supplemented with 5%
FBS and used in the sixth passage. For the uPA stimulation experi-
ments, the cells were cultured for 24 h in serum-free SmGM2 medium
and were then treated with uPA and lysed as described previously
[23,25]. The human fibrosarcoma HT1080 cell line was grown in
DMEM (Biochrom-Seromed) supplemented with 12% FBS, human
skin fibroblasts (primary culture, passage 5–6) and human umbilical
vein endothelial cell line ECV-304 were grown in growth medium
M199 EARLE (Biochrom-Seromed) supplemented with 10% FBS, the
LM–TK– cell line was grown in DMEM supplemented with 10% FBS.
Protein precipitation on the uPA-matrix, in vitro kinase assay,
immunoprecipitation, and ELISA
For the preparation of the uPA-matrix, recombinant wild-type uPA was
coupled to CNBr-activated Sepharose 4B (Pharmacia Biotech) as rec-
ommended by the manufacturer. As a control matrix, CNBr-activated
Sepharose 4B uncoupled and coupled with BSA was used. Cell
lysates (600–1000 µg total protein) were precleared at room tempera-
ture for 30 min with Sepharose 4B (Pharmacia Biotech), and were then
precipitated for 2 h at room temperature using the uPA-Sepharose,
which was previously blocked overnight with HEPES–NaCl buffer
(10 mM HEPES, 150 mM NaCl pH7.4) containing 1% BSA and 0.1%
Tween20. After incubation with precleared cell lysate, uPA-Sepharose
was washed five times with HEPES–NaCl buffer containing 0.1%
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Tween20 and once with kinase buffer (25 mM HEPES pH 7.2, 5 mM
MnCl2, 20 mM MgCl2, 1 mM sodium orthovanadate, 0.1% Nonidet
P40). The in vitro kinase reactions were performed as described else-
where [47], in 100 µl kinase buffer containing 10 µCi [γ-32P]ATP for
10 min at room temperature. Precipitates were washed subsequently
twice with 200 µl kinase buffer, eluted by Laemmli buffer, and sub-
jected to SDS–PAGE. The gels were Coomassie-stained, dried and
the phosphorylated proteins were then analyzed by autoradiography.
Western blot analysis of washed precipitates and immunoprecipitation
were performed as described elsewhere [23,25]. For uPAR ELISA,
cells were lysed as described above and the uPAR amount in the cell
lysates was measured using the uPAR ELISA Kit (#UR-5, Monozyme)
as advised by the manufacturers.
Enzymatic in-gel digestion and nano-electrospray mass
spectrometry
Protein bands containing highly phosphorylated proteins were recov-
ered in the Coomassie-stained gel and were cut out. The peptide
extracts were produced by in-gel tryptic cleavage of the protein [48] in
cleavage buffer (100 mM Tris-HCl pH 8.0, 1 mM CaCl2, 10% acetoni-
trile) containing 0.2–0.5 µg trypsin at 37°C for 15 h. After digestion,
the gel was incubated with two volumes 2% aqueous TFA at 60°C for
1 h. The techniques used for nano electrospray mass spectrometry are
described in detail elsewhere [49,50].
Immunofluorescent and electron microscopy studies
The techniques used for immunofluorescent microscopy are described
in detail elsewhere [51,52]. The images were acquired with NORAN
OZ (Noran Instruments) supported with InterVision 1.7. For electron
microscopy, pre-embedding double-staining was performed. Chilled
cells were incubated with a mixture of primary polyclonal anti-uPAR and
monoclonal anti-nucleolin antibodies (40 µg/ml of each antibody in pre-
cooled SmGM medium) at 4°C for 1 h, then were washed twice with
ice-cold HEPES–NaCl buffer, incubated with secondary antibodies
conjugated with 5 nm or 12 nm gold grains at 4°C for 1 h, and washed
twice again with ice-cold HEPES–NaCl buffer. For the investigation of
internalization events, cells were incubated with the secondary antibod-
ies at room temperature for 10 min. Labeled cells were immediately
fixed with 1% glutaraldehyde. After 1 h of fixation at room temperature,
the cells were rinsed with PBS, scraped off from the plates using a
rubber policeman, transferred into Eppendorf tubes, and centrifuged.
Cell pellets were then resuspended in a mixture of 20% polyvinylpyrroli-
done (PVP) and 1.8 M sucrose for at least 3–4 h and then mounted as
small droplets onto the specimen stubs and stored in liquid nitrogen.
Ultrathin cryosections were prepared using a REICHERT Ultracut S
ultramicrotome equipped with an FCS cryoattachment and transferred
to 100-mesh hexagonal formvar-carbon-coated grids with PVP —
sucrose droplets, washed with ddH2O and subsequently stained and
embedded in aqueous solution containing 2.8% polyvinylalcohol and
3% silicotungtic acid. The sections were observed and photographed
on a Philips EM 400 transmission electron microscope.
Cell proliferation assay
Cells were grown on a 48-well plate to 60% confluence in SmGM2
and deprived overnight in SmGM medium without supplements. Cells
were stimulated for 18 h with increasing concentrations of uPA in
serum-free medium without or in the presence of heparin (Sigma),
CK2-substrate peptide (RRREEETEEE, Alexis), and the RGG peptide;
as positive control and control for the specificity of the inhibition, 1%
serum were added. The DNA synthesis was measured using 5-bromo-
2‚-deoxy-uridine (BrdU) labeling and detection kit III (Roche) as advised
by the manufacturers.
Casein kinase-2 activity assay
For the measurements of CK2 activity, the cells were stimulated with
50 nM uPA, lysed, and subjected to immunoprecipitation as described
elsewhere [23,25] using antibodies against CK2, uPAR, or nucleolin.
CK2 activity was measured in the immunoprecipitates using the Casein
Kinase-2 assay kit (Upstate Biotechnology).
Statistics
Each experiment was repeated at least three times and representative
figures have been shown. For microscopy studies, at least 20–40 cells
from at least five separate experiments were examined under each
experimental condition.
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